Farmington, Connecticut-based Rallybio LLC, a biotech firm, has added Dr. Amanda Hayward and Lisa Sinclair to its team. Hayward will focus on building Rallybio’s portfolio while Sinclair will be focused on new product commercial planning including diagnostic and patient access approaches to support the portfolio. Rallybio’s backers include 5AM Ventures, Canaan Partners and New Leaf Venture Partners.
FARMINGTON, Conn.–(BUSINESS WIRE)–Rallybio LLC, a development-stage biotechnology company, today announced that it has further expanded its drug acquisition and development capabilities with the addition of Amanda Hayward, PhD and Lisa Sinclair, to the Rallybio team. Specifically, Dr. Hayward will focus on further building Rallybio’s portfolio and Ms. Sinclair will be focused on new product commercial planning including diagnostic and patient access approaches to support the portfolio. These leadership appointments further advance Rallybio’s mission to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders.
Amanda Hayward, PhD
Dr. Hayward brings more than 20 years of biopharmaceutical industry experience, specifically in venture capital, portfolio management, business development, and licensing transactions. Most recently, she served as Managing Director of Venture Investments for Connecticut Innovations. Previously, Dr. Hayward was Head of Business Development for Velocity Pharmaceuticals; President of Max Bio Strategy; Venture Partner for Connective Innovations; Partner for Baxalta Ventures; Acting CFO for Axerion Therapeutics; as well as having held positions of increasing responsibility for Scheer & Co., Inc., where she played a significant role in founding and growing multiple companies. She has significant board experience, and serves as Chairman of Hoba Therapeutics.
Dr. Hayward received her PhD in Cell Biology and Anatomy from Texas Tech University Health Sciences Center.
“We’re thrilled to welcome Amanda and look forward to applying her insight and expertise in identifying potential assets for Rallybio,” said Rallybio co-founder Dr. Martin Mackay. “Amanda’s proven track record of success in strategic investments, sourcing and evaluation will help lead the company into the next phase.”
“There is so much potential in the rare disorder space and I share the same passion and desire of my colleagues at Rallybio – to bring life-transforming treatments to patients,” said Dr. Hayward. “I am excited to join a team that has consistently proven themselves successful in the industry.”
Ms. Sinclair joins Rallybio with more than 20 years of experience in biopharmaceutical new product development, portfolio management and driving delivery of transformative medicines. She most recently served as Head of Program and Alliance Management for SpringWorks Therapeutics. Previously, Ms. Sinclair was Vice President of R&D Strategy, Portfolio and Project Management for Alexion Pharmaceuticals, as well as Vice President of Global R&D Portfolio and Performance for AstraZeneca. Earlier in her career, she held roles of increasing responsibility at Pfizer in portfolio and project management, therapeutic area management, clinical operations and sales.
Ms. Sinclair received a Bachelor of Arts in Business Administration from the University of Vermont.
“We are very pleased to welcome Lisa to the Rallybio team and look forward to leveraging her experience in creating innovative portfolio strategies,” said Dr. Mackay. “Lisa’s expertise in accelerating pipeline growth and lifecycle opportunities will continue to strengthen our commitment of bringing transformative treatments to patients.”
“I am passionate about bringing solutions to patients with rare disorders and am eager to apply my past experiences to advance Rallybio’s mission,” said Ms. Sinclair. “It is an honor to join a team that is so dedicated and driven to bringing transformative medicines to patients who have no effective treatments.”
Rallybio was established to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders. The founders of the company – Martin Mackay, PhD, Stephen Uden, MD, and Jeffrey Fryer, CPA – are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. Named by FierceBiotech as one of its “Fierce 15” Biotech Companies of 2018, the company was recognized as being among “the most promising private biotech startups”. Rallybio announced in April 2018 that it had secured $37.0 million in a Series A funding led by 5AM Ventures, Canaan Partners, and New Leaf Venture Partners, with additional public-sector participation from Connecticut Innovations. The Company is based in Farmington, CT, at the University of Connecticut’s Technology Incubation Program. For more information, please visit www.rallybio.com.